Eye­ing a block­buster mi­graine mar­ket, Al­ler­gan takes an in­side track on acute cas­es with pos­i­tive PhI­II

With a full slate of in­jectable CGRP mi­graine drugs po­si­tion­ing them­selves at the fin­ish line for FDA ap­provals for chron­ic cas­es, Al­ler­gan $AGN to­day took an­oth­er big step for­ward with its pill for acute cas­es. The com­pa­ny hailed a Phase III win for its first late-stage test of ubro­gepant, one of the mi­graine drugs it ac­quired from Mer­ck a lit­tle more than two years ago.

Re­searchers say the drug hit both of the co-pri­ma­ry end­points for acute mi­graine, with a sta­tis­ti­cal­ly sig­nif­i­cant beat for a place­bo arm in be­ing pain free and free of most symp­toms of mi­graine two hours af­ter ini­tial treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER